Jacobson TA - Search Results

1

The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology.

Virani SS, Aspry K, Dixon DL, Ferdinand KC, Heidenreich PA, Jackson EJ, Jacobson TA, McAlister JL, Neff DR, Gulati M, Ballantyne CM. Virani SS, et al. Among authors: jacobson ta. J Clin Lipidol. 2023 Mar-Apr;17(2):208-218. doi: 10.1016/j.jacl.2023.02.003. Epub 2023 Feb 27. J Clin Lipidol. 2023. PMID: 36965958 Free article.

2

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.

Jacobson TA. Jacobson TA. Am J Cardiol. 1996 Sep 26;78(6A):32-41. doi: 10.1016/s0002-9149(96)00660-1. Am J Cardiol. 1996. PMID: 8875973

3

Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.

Jacobson TA. Jacobson TA. Curr Opin Lipidol. 1997 Dec;8(6):369-74. doi: 10.1097/00041433-199712000-00008. Curr Opin Lipidol. 1997. PMID: 9412778 Review.

4

Maximizing the cost-effectiveness of lipid-lowering therapy.

Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Jacobson TA, et al. Arch Intern Med. 1998 Oct 12;158(18):1977-89. doi: 10.1001/archinte.158.18.1977. Arch Intern Med. 1998. PMID: 9778197 Review.

5

New perspectives on the management of low levels of high-density lipoprotein cholesterol.

Harper CR, Jacobson TA. Harper CR, et al. Among authors: jacobson ta. Arch Intern Med. 1999 May 24;159(10):1049-57. doi: 10.1001/archinte.159.10.1049. Arch Intern Med. 1999. PMID: 10335681 Review.

6

Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.

Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, Ballantyne CM. Jacobson TA, et al. Arch Intern Med. 2000 May 8;160(9):1361-9. doi: 10.1001/archinte.160.9.1361. Arch Intern Med. 2000. PMID: 10809042

7

Characteristics of US adults with the metabolic syndrome and therapeutic implications.

Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JC, Gause D, Varas C, Ballantyne CM. Jacobson TA, et al. Diabetes Obes Metab. 2004 Sep;6(5):353-62. doi: 10.1111/j.1462-8902.2004.00354.x. Diabetes Obes Metab. 2004. PMID: 15287928

8

The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?

Jacobson TA. Jacobson TA. Mayo Clin Proc. 2006 Sep;81(9):1225-31. doi: 10.4065/81.9.1225. Mayo Clin Proc. 2006. PMID: 16970219 Review.

9

The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.

Harper CR, Jacobson TA. Harper CR, et al. Among authors: jacobson ta. Curr Opin Lipidol. 2007 Aug;18(4):401-8. doi: 10.1097/MOL.0b013e32825a6773. Curr Opin Lipidol. 2007. PMID: 17620856 Review.

10

Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.

Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR. Davidson MH, et al. Among authors: jacobson ta. J Clin Lipidol. 2011 Sep-Oct;5(5):338-67. doi: 10.1016/j.jacl.2011.07.005. J Clin Lipidol. 2011. PMID: 21981835

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

208 results

Search Page